Literature DB >> 8398813

Expression of beta 2-microglobulin by human benign and malignant mesenchymal and neurogenic tumours.

B L Petersen1, O Braendstrup.   

Abstract

Human myosarcomas, liposarcomas, meningosarcomas, glioblastomas and malignant schwannomas, their benign counterparts and normal cells from which these tumours derive, were examined for the expression of beta 2-microglobulin (beta 2m). Formalin fixed specimens from these tumours were studied by light microscopy employing the immunoperoxidase method with the use of antibodies directed towards beta 2m. The malignant tumours showed a broad spectrum from unstained to strongly stained tumours, most pronounced among myosarcomas. In addition, most stained tumours displayed a mosaic staining pattern in that unstained areas alternated with stained. There was a tendency towards increased staining for beta 2m in malignant compared to normal cells; this was also observed in the benign tumours although to a lesser degree. The results differ from most earlier studies, mainly of carcinomas which have shown a tendency towards down-regulation of MHC I molecules on the tumour cells. The results are discussed in relation to concepts of immune surveillance of tumours.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8398813      PMCID: PMC2001843     

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  25 in total

1.  Differential expression of T cell differentiation antigens and major histocompatibility antigens on activated T cells during the cell cycle.

Authors:  Y Matsui; H M Shapiro; M J Sheehy; L Christenson; D E Staunton; E E Eynon; E J Yunis
Journal:  Eur J Immunol       Date:  1986-03       Impact factor: 5.532

2.  The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens.

Authors:  P J Bjorkman; M A Saper; B Samraoui; W S Bennett; J L Strominger; D C Wiley
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

Review 3.  The HLA system: structure and function.

Authors:  W F Bodmer
Journal:  J Clin Pathol       Date:  1987-09       Impact factor: 3.411

4.  Major histocompatibility antigens: the human (HLA-A, -B, -C) and murine (H-2K, H-2D) class I molecules.

Authors:  H L Ploegh; H T Orr; J L Strominger
Journal:  Cell       Date:  1981-05       Impact factor: 41.582

5.  Beta 2-microglobulin is not required for cell surface expression of the murine class I histocompatibility antigen H-2Db or of a truncated H-2Db.

Authors:  H Allen; J Fraser; D Flyer; S Calvin; R Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

Review 6.  The role of surface HLA-A,B,C molecules in tumour immunity.

Authors:  P Möller; G J Hämmerling
Journal:  Cancer Surv       Date:  1992

7.  Experimental strategies and interpretations in the analysis of changes in MHC gene expression during tumour progression. Opposing influences of T cell and natural killer mediated resistance?

Authors:  H G Ljunggren; K Kärre
Journal:  J Immunogenet       Date:  1986 Apr-Jun

8.  Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.

Authors:  K Kärre; H G Ljunggren; G Piontek; R Kiessling
Journal:  Nature       Date:  1986 Feb 20-26       Impact factor: 49.962

Review 9.  Immunological surveillance of tumors in the context of major histocompatibility complex restriction of T cell function.

Authors:  P C Doherty; B B Knowles; P J Wettstein
Journal:  Adv Cancer Res       Date:  1984       Impact factor: 6.242

10.  Rescue of Daudi cell HLA expression by transfection of the mouse beta 2-microglobulin gene.

Authors:  R H Seong; C A Clayberger; A M Krensky; J R Parnes
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

View more
  2 in total

Review 1.  The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice.

Authors:  I M Svane; M Boesen; A M Engel
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

2.  Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.

Authors:  Kellie B Haworth; Michael A Arnold; Christopher R Pierson; Kwangmin Choi; Nicholas D Yeager; Nancy Ratner; Ryan D Roberts; Jonathan L Finlay; Timothy P Cripe
Journal:  Oncotarget       Date:  2017-05-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.